Clinical trial myelofibrosis

Myelofibrosis is a rare chronic disorder that is most common for people over the age of 50 and it only affects 1. There are several active clinical trials available around the U. Cancer clinical trials are important for cancer treatment; they find and prove new ways to fight cancer. By participating in a clinical trial, you can find the best treatment for your Myelofibrosis Neoplasms and help others who are struggling with Myelofibrosis. There are approximately myelofibrosis clinical trials across the United States available for eligible patients to enroll in.

The latest drugs and therapies in cancer research are evaluated and compared to standard treatments. Participation in clinical trials helps further research and provides future patients access to new treatments. For rare diseases like myelofibrosis, there are a lack of new treatment options so clinical trials are important for the development of new drugs.

Contact Massive Bio for assistance in finding and enrolling into a clinical trial. Symptoms that can occur from myelofibrosis include anemia, skin planes, enlarging of the spleen and liver, portal hypertension, dilated veins in the stomach and esophagus, night sweats, blood clots, infections, fever, itching, bruising and bleeding, bone or joint pain, weight loss and extra medullary hematopoiesis.

Side effects from treatment can sometimes involve increase in platelets, which could lead to blood clots and worsening of anemia. Other possible side effects also include bruising, dizziness and headaches.

Some risk factors that may contribute to the increased potential of developing Myelofibrosis involve being exposed to ionizing radiation or petrochemicals such as benzene or toluene. Having a mutation in the JAK2 gene is also a contributing risk factor. Clinical trials offer new treatment opportunities for you and other Myelofibrosis patients by allowing experts in the medical field to research and test new procedures, treatments and practices before they are approved for standard treatment.

The clinical trial matching process is all virtual, which means there is no need to travel until you are completely enrolled into a clinical trial. Receive your clinical trial match results virtually, and speak with a patient advocate over the phone about eligibility and enrollment.

Our patient advocates receive your medical records and closely review your specific case to provide the best trial matches for your disease stage, biomarker status, geographical location and more.

I am looking for conjugated bilirubin. I am looking for direct bilirubin. I am looking for hydroxyurea. I am looking for tacrolimus. I am looking for janus kinase inhibitor. I am looking for cyclophosphamide. I am looking for busulfan. I am looking for imatinib. I am looking for melphalan. I am looking for immunosuppressive agents.

I am looking for pacritinib. I am looking for granulocyte colony stimulating factor. I am looking for colony stimulating factor. I am looking for anagrelide. These studies give hope for the future treatment of the disease. Clinical trials are a great alternative for patients who are not benefiting from other treatments. Myelofibrosis is a rare disease and can be seen in both men and women.

People of all ages can have myelofibrosis, but it is more often diagnosed in people over the age of The diagnosis of myelofibrosis is usually seen before the age of 3 in children. Myelofibrosis, a rare type of blood cancer, is considered a type of chronic leukemia. Acute leukemia may develop in some patients with myelofibrosis. Acute myelogenous leukemia, a type of rapidly progressing blood and bone marrow cancer, is one of the complications of myelofibrosis.

Other complications that may arise from myelofibrosis include increased blood pressure in the liver portal hypertension , abdominal and back pain due to enlargement of the spleen, and bleeding in the gastrointestinal system due to tumor formation. In , the discovery of JAK2 mutations enabled the development of a targeted therapy for patients with myelofibrosis. Fedratinib is another drug that has also been approved as the first treatment option for high-risk myelofibrosis.

Interferon is an immune therapy that helps reduce the excess of unhealthy blood cells and cytokines that cause fibrosis in the bone marrow. However, there may be significant side effects of interferon that may be difficult to tolerate for some patients. If you are looking for alternative treatment options, it is important to consult your doctor before making any decisions. Hi Maureen, thank you for your question, many drugs are currently in the clinical trial process, they are not yet FDA approved but patients can access them through clinical trials, we would be happy to discuss all available clinical trials with you.

Looking to try Pegasys. Dr tried to double dose and it was quickly overwhelming and stopped for 2 days. Other numbers mostly close to low normal. Any Pegasys trials?